Challenging surgical treatment of giant retroperitoneal liposarcoma: A case report

Liposarcoma is a rare malignant tumor type and surgical resection is the gold standard treatment. The present study reported on the case of a 51-year-old woman who presented with a mass in the left upper abdomen. Computed tomography revealed a 32-cm giant retroperitoneal liposarcoma. Complete tumor resection was performed without the removal of other organs. Postoperative pathological examination indicated retroperitoneal well-differentiated liposarcoma and immunohistochemistry revealed S-100(−), MDM2(+), vimentin(+), CDK4(+), p16(+) and STAT6(+) results. The patient recovered well after the surgery. Complete tumor resection during the first surgery is key to cure liposarcoma. The present case report will be helpful for clinical oncologists to fully understand giant retroperitoneal liposarcoma and treat it accordingly.     

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis

BackgroundNafamostat mesilate (NM), a broad-spectrum and potent serine protease inhibitor, can be used as an anticoagulant during extracorporeal circulation, as well as a promising drug effective against coronavirus disease 2019 (COVID-19). We conducted a systematic meta-analysis to evaluate the safety and efficacy of NM administration in critically ill patients who underwent blood purification therapy (BPT).MethodsThe Cochrane Library, Web of Science and PubMed were comprehensively searched from inception to August 20, 2021, for potential studies.ResultsFour randomized controlled trials (RCTs) and seven observational studies with 2723 patients met the inclusion criteria. The meta-analysis demonstrated that conventional therapy (CT) significantly increased hospital mortality compared with NM administration (RR = 1.25, p = 0.0007). In subgroup analyses, the in-hospital mortality of the NM group was significantly lower than that of the anticoagulant-free (NA) group (RR = 1.31, p = 0.002). The CT interventions markedly elevated the risk ratio of bleeding complications by 45% (RR = 1.45, p = 0.010) compared with NM interventions. In another subgroup analysis, NM used exhibited a significantly lower risk of bleeding complications than those of the low-molecular-weight heparin (LMWH) used (RR = 4.58, p = 0.020). The filter lifespan was decreased significantly (MD = −10.59, p < 0.0001) in the NA groups compared with the NM groups. Due to the poor quality of the included RCTs, these results should be interpreted with caution.ConclusionGiven the better survival outcomes, lower risk of bleeding, NM anticoagulation seems to be a safe and efficient approach for BPT patients and could yield a favorable filter lifespan. More multi-center RCTs with large samples are required for further validation of this study.     

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity

Axitinib is a potent vascular endothelial growth factor receptor (VEGFR) inhibitor, which has a strong inhibitory effect on the three isoforms of VEGFR 1–3. Having strong therapeutic efficacy, its broad use is limited by its side effects such as hypertension, proteinuria, cardiovascular damage, and liver and kidney dysfunction. Selenium compounds are broadly reported to have a good protective effect on cardiovascular disease, inflammation, infection, and immune function. In this study, a selenium substitute of axitinib was synthesized, and its anti-renal cell carcinoma activity and side effects were investigated. The results of the study indicated that Se-axitinib had potent antitumor activity on renal cell carcinoma (RCC), alleviated vascular hyperpermeability, and also alleviated axitinib-related side effects including hypertension, liver dysfunction and kidney dysfunction significantly. Therefore, we suggest that Se-axitinib could be a solution to the severe side effects of VEGFR inhibitors and provide evidence to improve the outcome of RCC treatment.

Se-axitinib is a selenium substitution of sulfur in axitinib, which reduced the side effect of VEGFR inhibitors and maintained the potent anticancer activity of the original drug.     

项目管理在提高门诊肠镜患者肠道准备合格率中的应用

目的 探讨项目管理在提高门诊肠镜患者肠道准备合格率中的应用效果.方法 成立项目管理团队,对门诊肠镜患者肠道准备合格率进行调查,找出影响合格率亟待改进的问题,实施项目管理,项目管理运用后再次进行调查,将调查结果与实施前进行比较.结果 项目管理实施后门诊肠镜患者肠道准备合格率显著高于实施前(P<0.01).结论 实施项目管...     

Nitrogen-doped graphene–poly(hydroxymethylated-3,4-ethylenedioxythiophene) nanocomposite electrochemical sensor for ultrasensitive determination of luteolin

An ultrasensitive luteolin electrochemical sensor was constructed by co-electropolymerization of nitrogen-doped graphene (N-GR) and hydroxymethylated-3,4-ethylenedioxythiophene (EDOT-MeOH) using cyclic voltammetry (CV). Because of the synergistic effects of the large surface area, superior electrical conductivity, and large amount of chemically active sites of N-GR together with the satisfactory water solubility and high conductivity of poly(hydroxymethylated-3,4-ethylenedioxythiophene) (PEDOT-MeOH), the N-GR–PEDOT-MeOH nanocomposite sensor exhibited high electrochemical sensitivity towards luteolin with a wide linear range of 0.005–10.06 μM and low detection limit of 0.05 nM. Satisfactory reproducibility, selectivity, and stability were exhibited by this electrochemical sensor. Additionally, the proposed sensor was employed for trace-level analysis of luteolin in actual samples of herbal medicines (thyme (Thymus vulgaris L.), honeysuckle (Lonicera japonica Thunb.), and Tibetan Duyiwei (Lamiophlomis rotata (Benth.) Kudo)) with satisfactory results.

A sensitive and selective electrochemical sensor was constructed by one-step co-electropolymerization of hydroxymethylated-3,4-ethylenedioxythiophene and nitrogen-doped graphene for the trace-level analysis of luteolin in Thymus vulgaris, Lonicera japonica, and Lamiophlomis rotata.     

三种问卷量表对妊娠期阻塞性睡眠呼吸暂停低通气综合征筛查价值的比较

目的 评价Epworth嗜睡量表、STOP-Bang问卷和Berlin问卷对妊娠期OSASH的筛查价值.方法 选取2019年6月至2020年6月于江西省妇幼保健院住院的打鼾孕妇87例作为研究对象,对受试者进行ESS、SBQ和Berlin问卷评分,并采用多导睡眠仪对受检者进行整夜不少于7h的PSG监测,采用ROC曲线比较...     

重庆地区梅毒螺旋体基因分型及其临床相关性研究

目的：调查重庆地区梅毒螺旋体基因亚型的分布,初步探讨基因亚型与临床相关性。方法：收集2010年6月至2013年10月重庆地区421例梅毒标本,用巢式PCR检测梅毒螺旋体DNA多聚酶I基因（DNA polymerase I gene,polA）,然后扩增阳性标本酸性重复蛋白基因（acid repeat protein,arp）和苍白密螺旋体重复家族基因（treponema pallidum repeat,tpr）及TP0548基因,分别根据Pillay标准基因分型和三基因分型法进行分型,利用双侧Fisher’s exact test进行数据统计分析,初步探讨不同基因亚型与血清固定、梅毒复发和吉海反应的相关性。结果：163例标本polA PCR检测阳性,arp、tpr基因和TP0548基因亚型分别以14型、d型和f型为主。正规驱梅治疗12月后,32例患者血清固定,其中tpr基因d型（1１例）、a和b型（各2例）和f型（1例）;3例患者梅毒复发,其中TP0548基因c型（2例）和f型（1例）;8例发生吉海反应,其中14f/f（4例）,14d/f（3例）和未分型（1例）。结论：重庆地区梅毒螺旋体以14、d和f型为优势型。梅毒血清固定可能与tpr基因b型相关,14f/f基因型的二期梅毒患者易发生苄星青霉素治疗后的吉海反应。     

经钛铝金属间化合物多孔材料分离后大黄虫丸对大鼠动脉血栓形成的影响

目的:采用不同孔径钛铝金属间化合物多孔材料(TAICPM)分离大黄虫丸,探讨经不同孔径TAICPM处理后的大黄虫丸抗动脉血栓形成的作用及机制。方法:选择70只SD雄性大鼠随机分为7组,其中正常组、模型组、对照组各10只,TAICPM组40只:1-5μm组、5-10μm组、10-15μm组、15-20μm组,每组各10只。血栓干重、血小板计数、血栓素B2(TXB-2)和6酮前列腺素F1α(6-keto-PGF1α)作为观察指标,评价经TAICPM分离后大黄虫丸抗动脉血栓形成的效果。结果:①对照组及TAICPM组血栓干重、血小板计数明显少于模型组(P<0.05),TXB-2和6-keto-PGF1α也较模型组有显著性差异(P<0.05);②TAICPM组血小板计数明显低于对照组(P<0.01),TXB-2和6-keto-PGF1α也较对照组有统计学差异(P<0.01);③1-5μm多孔材料组血栓干重明显低于其它3个多孔材料组(P<0.01),血小板计数、TXB-2和6-keto-PGF1α也较其它3组有显著性差异(P<0.01)。结论:经TAICPM处理后的大黄虫丸在抑制动脉血栓形成方面优于未处理的大黄虫丸,其中孔径为1-5μm的多孔材料效果更优。     

推拿教学课堂导入方式的探讨

推拿学是中医极具特色的临床学科,教学有其特点与规律.通过总结推拿教学中常用的6种形式即课程导入、案例导入、问题导入、媒体导入、预习导入、随时导入的方式并对推拿课堂的导入进行了相应的要求,如导入需要设计、相互关联、贯穿等,对推拿教学的课堂导入的地位、作用、目的等进行了探讨,为推拿教学提供参考.     

解聚复肾宁治疗早期2型糖尿病肾病

目的: 探讨解聚复肾宁治疗早期糖尿病肾病（DN）的临床疗效。 方法: 研究对象为我院收治的120例早期2型DN患者,将其随机分为解聚复肾宁组、厄贝沙坦组、解聚复肾宁+厄贝沙坦组、对照组。每组各30例,12周为1疗程,观察各组治疗前后相关指标的变化。 结果: 解聚复肾宁组治疗后空腹血糖、24 h尿微量白蛋白排泄率、血肌酐、糖化血红蛋白等指标显著好转,血清和尿液中血管紧张素Ⅱ（AngⅡ）,结缔组织生长因子（CTGF）均显著降低,解聚复肾宁和厄贝沙坦联合治疗明显优于两类药物单独应用（P<0.05）。 结论: 解聚复肾宁对早期2型DN疗效确切,可延缓病情进展,提高患者的生活质量,值得临床推广使用。